Compare SHO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | ZYME |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2004 | 2022 |
| Metric | SHO | ZYME |
|---|---|---|
| Price | $12.77 | $26.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $12.40 | ★ $43.23 |
| AVG Volume (30 Days) | ★ 3.1M | 1.2M |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | 0.43 | ★ 1.08 |
| Revenue | ★ $1,115,167,000.00 | $105,965,000.00 |
| Revenue This Year | $4.56 | $216.20 |
| Revenue Next Year | N/A | $7.81 |
| P/E Ratio | $29.64 | ★ $24.65 |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $8.69 | $21.52 |
| 52 Week High | $13.08 | $31.97 |
| Indicator | SHO | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 60.39 | 41.75 |
| Support Level | $12.19 | $25.21 |
| Resistance Level | $13.08 | $27.40 |
| Average True Range (ATR) | 0.28 | 1.41 |
| MACD | -0.05 | -0.33 |
| Stochastic Oscillator | 61.80 | 5.69 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.